Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 8/20 | 0.64 |
| ▸ | CES1 | P23141 | 8/20 | 0.64 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055116 | 0.94 | CES2 (0.57) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL27561994 | 0.86 | SRD5A2 (0.53) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL479072 | 0.84 | TSHR (0.65) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL3026551 | 0.84 | KCNQ3 (0.51) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL991621 | 0.83 | KCNQ3 (0.49) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| Hydrochloric Acid SCHEMBL9190175 | 0.83 | TSHR (0.63) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL1719358 | 0.83 | KCNQ3 (0.49) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL31163926 | 0.83 | KCNQ3 (0.49) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL2088683 | 0.83 | KCNQ3 (0.49) | CES2CES1KCNQ3KCNQ2KCNE1 | |
| Hydrochloric Acid SCHEMBL31439010 | 0.83 | TSHR (0.63) | CES2CES1KCNQ3KCNQ2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328524-B1 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-7652138-B2 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-26 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| EP-1328524-A2 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
| WO-2002032898-A2 | NOVEL ANTICHOLINERGICS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | CES2 337/4885CES1 383/4885KCNQ3 202/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | CES2 470/4885CES1 568/4885KCNQ3 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.